<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tension-type headache in adults: Preventive treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tension-type headache in adults: Preventive treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tension-type headache in adults: Preventive treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Frederick R Taylor, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tension-type headache (TTH) is characterized by a bilateral, nonthrobbing headache of a mild to moderate intensity, typically without other associated features. TTH is the most common headache and prevalent neurologic disorder in the population. Due to its high prevalence in the population, TTH causes a high degree of disability.</p><p>The preventive therapies of TTH in adults are reviewed here. Other aspects of TTH are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3358.html" rel="external">"Tension-type headache in adults: Acute treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6160.html" rel="external">"Tension-type headache in children"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>The preventive therapy of TTH ranges from drugs to nonpharmacologic therapies such as behavioral and cognitive interventions.</p><p class="headingAnchor" id="H3086865452"><span class="h2">Indication for preventive treatment</span><span class="headingEndMark"> — </span>Prophylactic headache treatment is indicated if the headaches are frequent, long lasting, or account for a significant amount of total disability [<a href="#rid1">1</a>]. With respect to TTH, both the frequent episodic subtype (1 to 14 headache days a month) and chronic subtype (≥15 headache days a month) warrant prevention as they may be associated with significant disability, especially when accompanied by migraine, comorbid depression, or anxiety [<a href="#rid2">2</a>].</p><p>Many patients with TTH who have up to 10 headache days per month can manage headaches with acute therapies, such as <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and nonsteroidal anti-inflammatory drugs. However, preventive therapy may also be indicated when acute therapy fails or is inappropriate because of inadequate response, adverse events, overuse, or contraindications.</p><p class="headingAnchor" id="H715328728"><span class="h2">Goals of treatment</span><span class="headingEndMark"> — </span>The goals of preventive therapy in TTH are reasonably extrapolated from those devised for migraine headache [<a href="#rid1">1</a>]. These include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduce attack frequency, severity, and duration</p><p class="bulletIndent1"><span class="glyph">●</span>Improve responsiveness to treatment of acute attacks</p><p class="bulletIndent1"><span class="glyph">●</span>Improve function and reduce disability</p><p></p><p>To achieve benefit, prophylactic headache therapy requires a sustained commitment on the part of the patient and clinician [<a href="#rid3">3</a>]. It is important to address patient expectations and consider patient preferences when deciding between different preventive therapies. In addition, the patient should be informed of the rationale for a particular treatment, the expected benefits of therapy, the duration of treatment that will likely be needed to achieve improvement, and the possible and likely side effects.</p><p class="headingAnchor" id="H1348055347"><span class="h2">Selection of therapies</span><span class="headingEndMark"> — </span>Preventive treatment should be individualized. Frequent TTH may be difficult to treat, but an acceptable result can usually be obtained by pharmacologic, nonpharmacologic, or a combination of nonpharmacologic and pharmacologic treatments [<a href="#rid4">4</a>].</p><p>Many patients who present with TTH have disabling symptoms, warranting a trial of pharmacotherapy. In addition, nondrug management should also be considered for all patients with TTH even though the scientific evidence is sparse and contradictory [<a href="#rid2">2</a>]. A therapeutic effect may be attained simply by taking the problem seriously, particularly if the patient is worried that the headache is caused by a serious problem such as a brain tumor. Behavioral treatments may be particularly well-suited for patients with the following conditions [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Those who prefer nonpharmacologic treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Those who have an insufficient response to, or poor tolerance of, pharmacologic treatments</p><p class="bulletIndent1"><span class="glyph">●</span>Females who are pregnant, planning to become pregnant, or nursing</p><p class="bulletIndent1"><span class="glyph">●</span>Those with a history of excessive use of analgesics or acute medications</p><p class="bulletIndent1"><span class="glyph">●</span>Those who have significant stress or deficient stress-coping skills</p><p></p><p class="headingAnchor" id="H3"><span class="h1">PHARMACOLOGIC THERAPIES</span><span class="headingEndMark"> — </span>A variety of pharmacologic therapies have been studied for the prophylactic treatment of TTH, as discussed in the sections that follow. Evidence of efficacy is limited and inconsistent [<a href="#rid6">6</a>], but perhaps is strongest for the tricyclic antidepressants such as <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>. Other medications that may be useful include the antidepressants <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a> and <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>, the anticonvulsants <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> and <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>, and the muscle relaxant <a class="drug drug_general" data-topicid="9999" href="/d/drug information/9999.html" rel="external">tizanidine</a>. In contrast, the available evidence suggests that the selective serotonin uptake inhibitors are not effective for TTH prophylaxis.</p><p class="headingAnchor" id="H4"><span class="h2">Tricyclic antidepressants</span><span class="headingEndMark"> — </span>Supporting evidence that tricyclics are beneficial for TTH comes from a 2017 meta-analysis [<a href="#rid7">7</a>]. At eight weeks compared with placebo in five trials, tricyclics reduced headache frequency (weighted mean difference -4.8 headaches per month, 95% CI -6.6 to -3.0) and analgesic medications use. However, the baseline headache frequency was approximately 21 headaches per month, so the benefit with tricyclics was considered moderate.</p><p>Tricyclic antidepressants are reuptake inhibitors of serotonin and noradrenaline, and these neurotransmitter interactions are the presumed mechanism of action for this class of drugs. Negative data regarding SSRIs suggest that other potential mechanisms, including inhibition of norepinephrine reuptake and antagonism of N-methyl-D-aspartate (NMDA) receptors, may be more likely to mediate the analgesic effect of tricyclics [<a href="#rid8">8</a>]. <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">Amitriptyline</a> also reduces pericranial muscle tenderness, leading to peripheral antinociception and inhibition of central sensitization [<a href="#rid9">9,10</a>]. Patients should be informed that amitriptyline is an antidepressant agent but has an independent action on pain [<a href="#rid2">2</a>]. The beneficial effect for TTH is not related to the presence of depression [<a href="#rid11">11</a>].</p><p>We suggest the use of <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> for patients with frequent episodic TTH or chronic TTH. Exceptions include patients with obesity, bipolar disease, or cardiac conduction defects. This recommendation is best suited for patients who have a preference for pharmacologic treatment rather than behavioral or other nonpharmacologic therapies. Our recommendation is in agreement with 2010 guidelines from the European Federation of Neurological Societies for the treatment of TTH, which conclude that amitriptyline has a clinically relevant prophylactic effect in patients with chronic TTH and should be the drug of first choice [<a href="#rid2">2</a>].</p><p>It is difficult to reach firm conclusions on the relative efficacy of tricyclics versus other treatment modalities as there are relatively few comparative trials [<a href="#rid7">7</a>]. The utility of combined tricyclic and behavioral therapy for the treatment of chronic TTH is reviewed below. (See <a class="local">'Combined behavioral and tricyclic therapy'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h3">Dosing and duration of therapy</span><span class="headingEndMark"> — </span>We suggest the following principles to guide preventive drug therapy for TTH:</p><p class="bulletIndent1"><span class="glyph">●</span>Start the drug at the lowest dose, and increase the dose gradually until therapeutic benefit is achieved, the maximum dose of the drug is reached, or side effects become intolerable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Give the prophylactic medication an adequate trial in terms of duration and dosage. Benefit is often first noted only after four to six weeks of therapy [<a href="#rid12">12,13</a>]. In addition, benefit may continue to accrue for three months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid overuse of analgesic medications. Ongoing analgesic overuse must be eliminated, or preventive therapy will likely be ineffective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measure the effectiveness of therapy by use of a patient headache diary to track daily headache frequency and intensity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once effective, maintain drug therapy for at least three to six months. Thereafter, a slow taper off the medication can be performed [<a href="#rid12">12</a>].</p><p></p><p>With these principles in mind, we start <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> at 10 to 12.5 mg nightly and increase the dose in 10 to 12.5 mg steps every two to three weeks as tolerated and as needed for sleep, until there is improvement in headache or until a maximum dose of 100 to 125 mg nightly is reached.</p><p>It is common for practitioners to initiate <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> at 25 mg each night and increase the dose in 25 mg increments each week, but in the author's clinical experience, such a regimen is complicated by increased side effects and reduced adherence compared with the one outlined above.</p><p><a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">Nortriptyline</a> and <a class="drug drug_general" data-topicid="9832" href="/d/drug information/9832.html" rel="external">protriptyline</a> can be considered as alternative tricyclics if <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> is poorly tolerated. The effects of these tricyclic medications on sleep, anxiety disorders, and body weight can guide the choice among them.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">Amitriptyline</a> is the most sedating, <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a> is mild to moderately sedating, while <a class="drug drug_general" data-topicid="9832" href="/d/drug information/9832.html" rel="external">protriptyline</a> is nonsedating and may be somewhat stimulating in some. Thus, protriptyline should be used cautiously for patients who have anxiety and panic disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">Amitriptyline</a> and <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a> can cause weight gain, while <a class="drug drug_general" data-topicid="9832" href="/d/drug information/9832.html" rel="external">protriptyline</a> may cause weight loss [<a href="#rid14">14</a>].</p><p></p><p><a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">Nortriptyline</a> is manufactured in capsules only and therefore is initiated and titrated in 10 or 25 mg increments and it can usually be increased on a weekly basis. <a class="drug drug_general" data-topicid="9832" href="/d/drug information/9832.html" rel="external">Protriptyline</a> is usually started at 5 mg each morning and increased in 5 mg increments every week with a target dose of 20 mg each morning.</p><p>Tricyclic medications are associated with an increased risk of cardiac conduction abnormalities and arrhythmias. Before initiating treatment with any of the cyclic antidepressants, patients should be screened for cardiac conduction system disease, which precludes the use of these medications. We and others suggest that patients age 40 years and older have a baseline electrocardiogram (ECG) for this purpose. Patients younger than age 40 can be screened by history for evidence of cardiac disease. They do not require an ECG if the history is negative. Patients who have a normal ECG before starting a tricyclic antidepressant do not need additional ECG monitoring while on the antidepressant, unless symptoms arise suggestive of cardiac toxicity. (See  <a class="medical medical_review" href="/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects", section on 'Cardiac evaluation'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Other antidepressants</span><span class="headingEndMark"> — </span>Limited data from small randomized controlled trials suggest that <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a> (a noradrenergic and specific serotonergic antidepressant) and <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> (a serotonin-norepinephrine reuptake inhibitor) may be effective for the treatment of chronic TTH in patients without depression.</p><p class="bulletIndent1"><span class="glyph">●</span>In an eight-week trial involving 24 patients with chronic TTH, including subjects not responsive to <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a> (15 to 30 mg daily) treatment was associated with a 34 percent lower area under the headache curve (the sum of the daily recordings of headache duration multiplied by headache intensity), the primary outcome measure, than placebo, and the difference was statistically significant [<a href="#rid15">15</a>]. In addition, mirtazapine treatment was associated with statistically significant reductions in headache intensity, duration, and frequency.</p><p></p><p class="bulletIndent1">More patients treated with <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a> had sedation, dizziness, and weight gain than did patients receiving placebo, but the difference was not statistically significant. However, weight gain is a known side effect of mirtazapine, and the short duration of the trial may explain why the relationship did not achieve statistical significance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 12-week trial involving 60 patients with TTH and more than five headaches a month at entry, treatment with extended-release <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> (150 mg daily) was associated with a statistically significant reduction in days with headache, the primary outcome measure, compared with placebo (45 percent reduction versus 16 percent increase) [<a href="#rid16">16</a>]. However, there were no statistically significant differences between treatment groups on any of the secondary outcome measures. Adverse events, mainly gastrointestinal symptoms, were more frequent in the venlafaxine group.</p><p></p><p>These results appear promising, but are limited. <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">Mirtazapine</a> is markedly higher priced than <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> while comparative cost-effectiveness research is lacking. We believe the effectiveness of mirtazapine and <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> for TTH prevention requires further confirmation in larger trials before either can be recommended as a routine treatment. The 2010 European guidelines consider mirtazapine and venlafaxine to be drugs of second choice for the prophylactic treatment of chronic TTH [<a href="#rid2">2</a>].</p><p>Available evidence suggests that selective serotonin reuptake inhibitors are <strong>not</strong> effective for the treatment of TTH in patients without depression [<a href="#rid12">12</a>]. This conclusion is supported by a meta-analysis published in 2015, which found that SSRIs did not show any benefit compared with placebo for patients with TTH [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Anticonvulsants</span><span class="headingEndMark"> — </span>Limited evidence suggests that <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> and <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> may be beneficial for patients with chronic TTH.</p><p class="bulletIndent1"><span class="glyph">●</span>Direct evidence of benefit for <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> in TTH prevention is lacking, but one randomized trial evaluated this drug in 95 patients with chronic daily headache, including 25 patients with TTH and 58 with a combination of TTH and migraine [<a href="#rid18">18</a>]. Treatment with gabapentin (2400 mg daily) was associated with a statistically significant improvement in headache-free days compared with placebo. The strength of this finding is limited by methodologic problems with the study, including failure to use an intention-to-treat analysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An open-label study of <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> (initially 25 mg daily, then increased to 100 mg daily) in 51 patients with TTH reported a significant decline in headache frequency after three months of treatment [<a href="#rid19">19</a>].</p><p></p><p>Further evidence from randomized clinical trials is needed to clarify whether <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> have a role in TTH prevention.</p><p class="headingAnchor" id="H9"><span class="h2">Tizanidine</span><span class="headingEndMark"> — </span>There is limited and conflicting data regarding the effectiveness of <a class="drug drug_general" data-topicid="9999" href="/d/drug information/9999.html" rel="external">tizanidine</a>, a muscle relaxant and antispasticity agent, for the prophylaxis of TTH [<a href="#rid20">20-23</a>]. An early clinical trial of 37 females with chronic TTH found that tizanidine (6 to 18 mg daily) was more effective than placebo [<a href="#rid20">20</a>]. However, a larger trial of 185 patients with chronic TTH showed that tizanidine (6 or 12 mg modified release daily) was without benefit compared with placebo [<a href="#rid21">21</a>].</p><p>An open-label trial of 18 subjects with chronic TTH reported that combined treatment with <a class="drug drug_general" data-topicid="9999" href="/d/drug information/9999.html" rel="external">tizanidine</a> (4 mg daily for three weeks) and <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> (20 mg daily for three months) led to faster reduction in headache frequency, intensity, and duration than amitriptyline alone [<a href="#rid24">24</a>]. The small size and open-label nature of this trial precludes definitive conclusions.</p><p class="headingAnchor" id="H331018097"><span class="h2">Local injection treatments</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trigger point injections</strong> – Trigger point injections require more research, but limited data from small randomized controlled trials suggest that <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> injections may reduce headache frequency and, thereby, total acute medication use for patients with frequent episodic or chronic TTH [<a href="#rid25">25,26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Botulinum toxin injections</strong> – In a 2023 meta-analysis, 11 placebo-controlled trials evaluated <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> (botulinum toxin type A) for patients with chronic TTH [<a href="#rid27">27</a>]. Quality of evidence was low to moderate. Botulinum toxin injections led to a small reduction in the frequency, duration, and intensity of headaches, as well as lower use of acute pain medications. However, the absolute response rate with botulinum toxin injections was 12 percent, suggesting benefit of this therapy for unselected patients with TTH may only benefit a minority of patients. Given these data, the use of botulinum toxin injections for the preventive treatment of TTH is of uncertain benefit.</p><p></p><p class="headingAnchor" id="H11"><span class="h1">BEHAVIORAL THERAPIES</span><span class="headingEndMark"> — </span>The goal of behavioral treatments is to prevent headaches by identifying and defusing headache triggers, which are particularly important in TTH, and by using self-regulation to modulate involuntary and subconscious physiologic processes [<a href="#rid28">28</a>]. Behavioral treatments for headache include the following methods [<a href="#rid5">5,28,29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Regulation of sleep, exercise, and meals</p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive-behavioral therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Relaxation</p><p class="bulletIndent1"><span class="glyph">●</span>Biofeedback</p><p class="bulletIndent1"><span class="glyph">●</span>Combinations of the above (eg, stress management therapy often consists of a combination of behavioral methods, with an emphasis on cognitive-behavioral therapy)</p><p></p><p>Identifying the triggering or exacerbating factors for headache may be important for success in headache therapy. Epidemiologic studies suggest that stress and mental tension are the most frequent identified triggers for TTH [<a href="#rid30">30</a>]. Coping with headache triggers is probably a more valuable strategy than advice to avoid the triggers [<a href="#rid31">31</a>]. Since there is an important behavioral component to nearly all of the known headache triggers, behavioral therapies are a potentially useful means of coping with and/or alleviating these triggers [<a href="#rid5">5</a>].</p><p>A 2009 review of randomized trials evaluating behavioral treatments for chronic TTH included 44 trials with 2618 patients, but only five studies were considered to have low risk of bias [<a href="#rid32">32</a>]. Most trials lacked adequate statistical power, and rates of recovery or improvement frequently failed to reach clinical relevance. In 11 studies, biofeedback was compared with waitlist conditions, and in eight studies, relaxation treatment was compared with waitlist conditions, both showing inconsistent results.</p><p class="headingAnchor" id="H848296188"><span class="h2">First-line therapies</span><span class="headingEndMark"> — </span>We suggest treatment using biofeedback combined with relaxation therapy rather than other behavioral therapy options for patients with frequent episodic TTH or chronic TTH. This recommendation is similar to the conclusions of the 2010 European guidelines for the treatment of TTH, which observed that there is no convincing evidence to support an effect of cognitive-behavioral therapy and relaxation training alone for TTH [<a href="#rid2">2</a>].</p><p>A 2008 meta-analysis of biofeedback for TTH included 53 studies and concluded that biofeedback was more effective than headache monitoring, placebo, and relaxation therapies [<a href="#rid33">33</a>]. In addition, the effect was long-lasting and enhanced by combination with relaxation therapy [<a href="#rid2">2,33</a>].</p><p>Nevertheless, cognitive-behavioral or combination therapies may be beneficial for patients with TTH who have underlying behavioral triggers or those who do not respond to other treatments. (See <a class="local">'Alternative options'</a> below.)</p><p class="headingAnchor" id="H482163804"><span class="h3">Biofeedback</span><span class="headingEndMark"> — </span>Biofeedback methods are based upon the notion that an individual can learn to control involuntary and subconscious physiologic processes when information about these processes is fed back in the form of a visual or auditory signal [<a href="#rid28">28</a>]. Electromyography feedback is the predominant method used in TTH treatment.</p><p>Pericranial muscle tenderness is often associated with TTH, but many patients are either not aware of the relationship, or overly fixate on its importance. Biofeedback may be helpful in either circumstance.</p><p class="headingAnchor" id="H1114182744"><span class="h3">Relaxation</span><span class="headingEndMark"> — </span>Relaxation techniques are based upon the premise that an unwanted outcome, such as headache, can be diminished or avoided by altering physiologic responses and decreasing sympathetic arousal [<a href="#rid28">28</a>]. Various forms of relaxation include progressive muscle relaxation, autogenic training (ie, learning self-statements that suggest warmth and heaviness), meditative or passive relaxation, and self-hypnosis.</p><p class="headingAnchor" id="H1117564053"><span class="h2">Alternative options</span></p><p class="headingAnchor" id="H12"><span class="h3">Cognitive-behavioral therapy</span><span class="headingEndMark"> — </span>Cognitive-behavioral therapy combines principles of cognitive therapy, which teaches patients to identify, evaluate, and better respond to their dysfunctional thoughts and beliefs, and behavior therapy, which helps patients develop new and adaptive ways of behaving.</p><p>As applied to headache, cognitive-behavioral therapy attempts to modify a maladaptive response (eg, headache) to stressful events by altering the usual interpretations, thoughts, and assumptions associated with such events [<a href="#rid28">28</a>]. Identifying headache triggers (whether physical, psychologic, or behavioral) and developing effective coping strategies are important aspects of this therapy.</p><p class="headingAnchor" id="H16"><span class="h3">Combined behavioral and tricyclic therapy</span><span class="headingEndMark"> — </span>Although data are limited, behavioral therapy and tricyclic therapy appear to have equivalent modest effectiveness for the treatment of chronic TTH, while tricyclic therapy achieves benefit more rapidly. In addition, a combination of the two therapies may be superior to either alone.</p><p>Supporting evidence comes from a clinical trial that randomly assigned 203 patients with chronic TTH to one of four treatment arms: tricyclic antidepressant treatment, placebo, stress management plus placebo, or stress management plus tricyclic antidepressant [<a href="#rid34">34</a>].</p><p>Patients assigned to tricyclics received <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> (12.5 mg to 100 mg nightly as tolerated); <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a> (25 mg to 75 mg nightly as tolerated) was substituted if amitriptyline was poorly tolerated or ineffective [<a href="#rid34">34</a>]. Stress management therapy consisted of the following elements: three one-hour teaching sessions and two telephone contacts with a psychologist or counselor, instruction manuals and audio tapes to guide home-based stress management skills, deep muscle relaxation training, and cognitive coping or problem-solving techniques to manage and prevent headache-related stress.</p><p>The following outcomes were reported [<a href="#rid34">34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Compared with placebo, all three active treatments (tricyclic antidepressant, stress management plus placebo, or stress management plus tricyclics) were associated with similar, statistically significant improvements in the headache index (a measure of overall headache activity) at six months, the primary outcome measure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The magnitude of benefit was modest for all active treatments; each reduced the number of days a month with a headache of moderate or greater severity by half (from approximately 14 to 7 days).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tricyclic treatment was associated with a more rapid improvement in headache index scores than stress management alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tricyclic treatment was also associated with significantly more adverse events, mainly dry mouth and drowsiness, than placebo treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The proportion of patients who achieved a clinically significant (ie, ≥50 percent) reduction in headache index scores was higher in the combined stress management plus tricyclics treatment group than in the tricyclic only group (64 versus 38 percent), and the difference was statistically significant.</p><p></p><p>Given these data, and despite limited evidence supporting benefit, we suggest treatment with combined tricyclic antidepressant therapy plus stress management therapy for patients with frequent episodic TTH or chronic TTH, rather than treatment with tricyclics alone or behavioral therapy alone. This recommendation is best suited for patients who are willing to undergo both pharmacologic and nonpharmacologic treatments.</p><p class="headingAnchor" id="H17"><span class="h3">Self-management</span><span class="headingEndMark"> — </span>Although there are few data, many experts believe that a behavioral self-management program is important to minimize disease progression in the preventive treatment of TTH [<a href="#rid5">5</a>]. A potential advantage of these methods is that they encourage greater responsibility on the part of the patient to engage in health promotion, while maintaining essential collaboration between patient and practitioner [<a href="#rid5">5</a>].</p><p>Self-management involves developing knowledge of headache triggers with attention to reducing these triggers. For headache in general, this process includes attention to sleep problems, lack of exercise, medication and <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> overuse, stress related to life events, and any other obvious factors. For TTH in particular, the emphasis of self-management is focused on developing stress awareness and control.</p><p class="headingAnchor" id="H18"><span class="h2">Implementation</span><span class="headingEndMark"> — </span>Behavioral treatments can be applied in a clinic-based format with sessions involving one-to-one contact between the patient and a psychologist or counselor [<a href="#rid5">5</a>]. Alternative formats for delivery of behavioral self-management techniques include small-group therapy and home-based (minimal-contact) treatment [<a href="#rid5">5</a>].</p><p>While some individuals can gain expertise through self-learning via commercially available videos or internet-based programs, current evidence supports professional application. Referral to a community-based pain psychologist is advised if the practitioner does not have access to readily available behavioral therapy resources.</p><p class="headingAnchor" id="H19"><span class="h1">OTHER NONPHARMACOLOGIC THERAPIES</span><span class="headingEndMark"> — </span>Nonpharmacologic interventions for TTH include heat, ice, acupuncture, manual therapies (including osteopathic manipulation and massage), rest, and biofeedback.</p><p class="headingAnchor" id="H20"><span class="h2">Acupuncture</span><span class="headingEndMark"> — </span>The available evidence regarding acupuncture for TTH suggests that any benefit is likely to be modest.</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis updated in 2016 identified seven randomized trials with sham controls [<a href="#rid35">35</a>]. While there was a statistically significant benefit for the primary outcome, the proportion of patients who achieved a ≥50 percent reduction of headache frequency, the effect size was small; the quality of the evidence was moderate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one of the larger individual trials that used 42 trained physician acupuncturists [<a href="#rid36">36</a>] and enrolled 270 patients with chronic TTH, acupuncture treatment was associated with a statistically significant benefit of fewer days with headache compared with no treatment (ie, wait list controls), but acupuncture was not beneficial compared with minimal (sham) acupuncture [<a href="#rid37">37</a>]. This result suggests that treatment with any acupuncture technique may have measurable therapeutic effects [<a href="#rid36">36</a>].</p><p></p><p>Although of limited benefit for the prevention of TTH, acupuncture is safe and may be used for patients who do not tolerate or desire more effective treatments such as <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>.</p><p class="headingAnchor" id="H21"><span class="h2">Physical therapies</span><span class="headingEndMark"> — </span>The benefit of physical therapy for TTH is unproven, though some studies suggest promise [<a href="#rid38">38</a>]. Various physical therapy methods, alone or in combination, have been used to treat TTH, including specific exercises, therapeutic heat or cold, massage, postural correction, therapeutic touch, traction, inactivation of muscle trigger points, spinal manipulation, and electrical therapies such as transcutaneous electrical nerve stimulation (TENS), electromagnetic therapy, ultrasound, and laser [<a href="#rid2">2,39</a>]. Osteopathic manipulative therapy uses a variety of techniques including massage, low velocity manipulations, and postural correction, depending on body area. Proposed methods for inactivating muscle trigger points include dry needling, ultrasound, laser, electrotherapy, and manual therapies [<a href="#rid40">40,41</a>]. However, the best technique is not yet defined, nor is it known if there is any particular subgroup of patients who are more likely to respond to this method.</p><p>Unfortunately, there are few high-quality randomized double-blind placebo-controlled trials evaluating the effectiveness of physical therapy for TTH prevention. The evidence is summarized by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>A 2014 systematic review identified six randomized controlled trials evaluating manual therapies that involved 249 subjects with TTH (mostly chronic TTH) [<a href="#rid42">42</a>]. One trial evaluated massage and five evaluated physiotherapy. Only two studies avoided co-intervention, leading to potential problems with bias and interpretation of the results.</p><p></p><p class="bulletIndent1">In one of the larger trials included in the systematic review, 81 patients with TTH were randomly assigned to a program of craniocervical endurance exercises combined with standard physical therapy (massage, oscillation techniques, postural correction) or to physical therapy alone [<a href="#rid43">43</a>]. At six weeks, combined craniocervical training plus physical therapy was associated with a nonsignificant reduction in headache frequency compared with physical therapy alone, but the benefit was sustained, and the reduction in headache frequency was statistically significant at six months (1.95 fewer headaches per week, 95% CI 1.14-2.76). Furthermore, headache intensity and duration at six months were significantly reduced with combined treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis identified five small randomized controlled trials that compared various multimodal manual therapies (eg, spine mobilization or manipulation, low-load stabilization exercises, soft tissue pressure release, and postural correction) with pharmacologic interventions [<a href="#rid44">44</a>]. In pooled data, manual therapies were associated with reduced headache frequency compared with pharmacologic therapies at two weeks; there was no significant difference at longer time points. Major limitations included lack of blinding (only one of the trials blinded assessors and none blinded therapists or subjects) and heterogeneity of the treatments.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single-blind randomized controlled trial pilot study of 40 subjects with frequent episodic TTH not on prophylactic regimens that randomly assigned patients to corrective osteopathic manipulative therapy or sham therapy, active treatment led to a significant improvement in headache frequency at one and three months, with an absolute reduction in headache frequency at three months of 33 percent [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of three clinical trials found strength training produced a moderate improvement in pain intensity, but the certainty of these results was very low due to small number of patients assessed, risk of bias, and varied protocols used [<a href="#rid46">46</a>].</p><p></p><p>Given the lack of definitive evidence of benefit for physical therapy, its role in the preventive treatment of TTH remains unclear. However, these treatments are associated with a low risk of serious side effects [<a href="#rid38">38,39</a>]. We suggest treatment with physical therapy that includes craniocervical exercises for patients with frequent episodic TTH and chronic TTH who do not tolerate or desire more effective treatments such as <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> and behavioral therapy.</p><p class="headingAnchor" id="H1455213123"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H4188754"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (See  <a class="medical medical_patient" href="/d/html/720.html" rel="external">"Patient education: Headache treatment in adults (Beyond the Basics)"</a>.)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for and approach to treatment</strong> – Prophylactic headache treatment is indicated if headaches are frequent, long lasting, or associated with a significant amount of disability. Preventive therapy may be also indicated when acute therapy fails or is inappropriate because of inadequate response, adverse events, overuse, or contraindications. (See <a class="local">'Approach to treatment'</a> above.)</p><p></p><p class="bulletIndent1">Treatment should be individualized. Frequent tension-type headache (TTH) may be difficult to treat, but an acceptable result can usually be obtained by a combination of nonpharmacologic and pharmacologic treatments. (See <a class="local">'Selection of therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic treatment options</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tricyclic antidepressants </strong>– For patients with frequent episodic TTH or chronic TTH who have a preference for pharmacologic treatment rather than behavioral therapy, we suggest tricyclic therapy with <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We start amitriptyline at 10 to 12.5 mg nightly and increase the dose in 10 to 12.5 mg steps every two to three weeks as tolerated and as needed for sleep, until there is improvement in headache up to a maximum dose of 100 to 125 mg nightly. Onset of benefit may be delayed until after four to six weeks of therapy. Once effective, we maintain medication therapy for three to six months prior to attempting a slow taper. (See <a class="local">'Tricyclic antidepressants'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other pharmacotherapies</strong> – Other medications for TTH prophylaxis include serotonin-norepinephrine reuptake inhibitors (<a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a> and <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>) and anticonvulsants (<a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>). However, the benefit of these drugs for TTH prevention is not well established, and more clinical trial data are required. (See <a class="local">'Other antidepressants'</a> above and <a class="local">'Anticonvulsants'</a> above and <a class="local">'Tizanidine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavioral treatments</strong> – For patients with frequent episodic TTH or chronic TTH who wish to avoid pharmacologic therapy, we suggest electromyography biofeedback combined with relaxation therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Other behavioral treatment options include cognitive-behavioral therapy and regulation of sleep, exercise, and meals. (See <a class="local">'Behavioral therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy for patients with frequent headaches</strong> – For patients with frequent episodic TTH or chronic TTH, we suggest treatment with combined tricyclic antidepressant therapy plus stress management therapy rather than treatment with tricyclics alone or behavioral therapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Combined behavioral and tricyclic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other nonpharmacologic treatments</strong> – For patients with frequent episodic TTH and chronic TTH who do not tolerate or desire more effective treatments such as <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> and biofeedback, we suggest treatment with acupuncture (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>) or physical therapy that includes craniocervical exercises, osteopathic manipulation therapy, or inactivation of muscle trigger points (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Other nonpharmacologic therapies'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.</a></li><li><a class="nounderline abstract_t">Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 2010; 17:1318.</a></li><li><a class="nounderline abstract_t">Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22:491.</a></li><li><a class="nounderline abstract_t">Bendtsen L, Jensen R. Treating tension-type headache -- an expert opinion. Expert Opin Pharmacother 2011; 12:1099.</a></li><li><a class="nounderline abstract_t">Penzien DB, Rains JC, Lipchik GL, Creer TL. Behavioral interventions for tension-type headache: overview of current therapies and recommendation for a self-management model for chronic headache. Curr Pain Headache Rep 2004; 8:489.</a></li><li><a class="nounderline abstract_t">Verhagen AP, Damen L, Berger MY, et al. Lack of benefit for prophylactic drugs of tension-type headache in adults: a systematic review. Fam Pract 2010; 27:151.</a></li><li><a class="nounderline abstract_t">Jackson JL, Mancuso JM, Nickoloff S, et al. Tricyclic and Tetracyclic Antidepressants for the Prevention of Frequent Episodic or Chronic Tension-Type Headache in Adults: A Systematic Review and Meta-Analysis. J Gen Intern Med 2017; 32:1351.</a></li><li><a class="nounderline abstract_t">Ashina S, Bendtsen L, Jensen R. Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. Pain 2004; 108:108.</a></li><li><a class="nounderline abstract_t">Bendtsen L, Jensen R. Amitriptyline reduces myofascial tenderness in patients with chronic tension-type headache. Cephalalgia 2000; 20:603.</a></li><li><a class="nounderline abstract_t">Bendtsen L. Central sensitization in tension-type headache--possible pathophysiological mechanisms. Cephalalgia 2000; 20:486.</a></li><li><a class="nounderline abstract_t">Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry 1996; 61:285.</a></li><li><a class="nounderline abstract_t">Lenaerts ME. Pharmacoprophylaxis of tension-type headache. Curr Pain Headache Rep 2005; 9:442.</a></li><li><a class="nounderline abstract_t">Göbel H, Hamouz V, Hansen C, et al. Chronic tension-type headache: amitriptyline reduces clinical headache-duration and experimental pain sensitivity but does not alter pericranial muscle activity readings. Pain 1994; 59:241.</a></li><li><a class="nounderline abstract_t">Cohen GL. Protriptyline, chronic tension-type headaches, and weight loss in women. Headache 1997; 37:433.</a></li><li><a class="nounderline abstract_t">Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004; 62:1706.</a></li><li><a class="nounderline abstract_t">Zissis NP, Harmoussi S, Vlaikidis N, et al. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia 2007; 27:315.</a></li><li><a class="nounderline abstract_t">Banzi R, Cusi C, Randazzo C, et al. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults. Cochrane Database Syst Rev 2015; :CD011681.</a></li><li><a class="nounderline abstract_t">Spira PJ, Beran RG, Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 2003; 61:1753.</a></li><li><a class="nounderline abstract_t">Lampl C, Marecek S, May A, Bendtsen L. A prospective, open-label, long-term study of the efficacy and tolerability of topiramate in the prophylaxis of chronic tension-type headache. Cephalalgia 2006; 26:1203.</a></li><li><a class="nounderline abstract_t">Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study. Headache 1992; 32:509.</a></li><li><a class="nounderline abstract_t">Murros K, Kataja M, Hedman C, et al. Modified-release formulation of tizanidine in chronic tension-type headache. Headache 2000; 40:633.</a></li><li><a class="nounderline abstract_t">Saper JR, Lake AE 3rd, Cantrell DT, et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002; 42:470.</a></li><li><a class="nounderline abstract_t">Warner JS. Tizanidine is not a cure for chronic daily headache. Headache 2003; 43:296; author reply 296.</a></li><li><a class="nounderline abstract_t">Bettucci D, Testa L, Calzoni S, et al. Combination of tizanidine and amitriptyline in the prophylaxis of chronic tension-type headache: evaluation of efficacy and impact on quality of life. J Headache Pain 2006; 7:34.</a></li><li><a class="nounderline abstract_t">Karadaş Ö, Inan LE, Ulaş Ü, Odabaşi Z. Efficacy of local lidocaine application on anxiety and depression and its curative effect on patients with chronic tension-type headache. Eur Neurol 2013; 70:95.</a></li><li><a class="nounderline abstract_t">Karadaş Ö, Gül HL, Inan LE. Lidocaine injection of pericranial myofascial trigger points in the treatment of frequent episodic tension-type headache. J Headache Pain 2013; 14:44.</a></li><li><a class="nounderline abstract_t">Dhanasekara CS, Payberah D, Chyu JY, et al. The effectiveness of botulinum toxin for chronic tension-type headache prophylaxis: A systematic review and meta-analysis. Cephalalgia 2023; 43:3331024221150231.</a></li><li><a class="nounderline abstract_t">Rains JC, Penzien DB, McCrory DC, Gray RN. Behavioral headache treatment: history, review of the empirical literature, and methodological critique. Headache 2005; 45 Suppl 2:S92.</a></li><li><a class="nounderline abstract_t">Penzien DB, Rains JC, Andrasik F. Behavioral management of recurrent headache: three decades of experience and empiricism. Appl Psychophysiol Biofeedback 2002; 27:163.</a></li><li><a class="nounderline abstract_t">Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 1993; 53:65.</a></li><li><a class="nounderline abstract_t">Martin PR, MacLeod C. Behavioral management of headache triggers: Avoidance of triggers is an inadequate strategy. Clin Psychol Rev 2009; 29:483.</a></li><li><a class="nounderline abstract_t">Verhagen AP, Damen L, Berger MY, et al. Behavioral treatments of chronic tension-type headache in adults: are they beneficial? CNS Neurosci Ther 2009; 15:183.</a></li><li><a class="nounderline abstract_t">Nestoriuc Y, Rief W, Martin A. Meta-analysis of biofeedback for tension-type headache: efficacy, specificity, and treatment moderators. J Consult Clin Psychol 2008; 76:379.</a></li><li><a class="nounderline abstract_t">Holroyd KA, O'Donnell FJ, Stensland M, et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. JAMA 2001; 285:2208.</a></li><li><a class="nounderline abstract_t">Linde K, Allais G, Brinkhaus B, et al. Acupuncture for the prevention of tension-type headache. Cochrane Database Syst Rev 2016; 4:CD007587.</a></li><li><a class="nounderline abstract_t">Melchart D, Streng A, Hoppe A, et al. The acupuncture randomised trial (ART) for tension-type headache--details of the treatment. Acupunct Med 2005; 23:157.</a></li><li><a class="nounderline abstract_t">Melchart D, Streng A, Hoppe A, et al. Acupuncture in patients with tension-type headache: randomised controlled trial. BMJ 2005; 331:376.</a></li><li><a class="nounderline abstract_t">Luedtke K, Allers A, Schulte LH, May A. Efficacy of interventions used by physiotherapists for patients with headache and migraine-systematic review and meta-analysis. Cephalalgia 2016; 36:474.</a></li><li><a class="nounderline abstract_t">Bronfort G, Nilsson N, Haas M, et al. Non-invasive physical treatments for chronic/recurrent headache. Cochrane Database Syst Rev 2004; :CD001878.</a></li><li><a class="nounderline abstract_t">Alonso-Blanco C, de-la-Llave-Rincón AI, Fernández-de-las-Peñas C. Muscle trigger point therapy in tension-type headache. Expert Rev Neurother 2012; 12:315.</a></li><li><a class="nounderline abstract_t">France S, Bown J, Nowosilskyj M, et al. Evidence for the use of dry needling and physiotherapy in the management of cervicogenic or tension-type headache: a systematic review. Cephalalgia 2014; 34:994.</a></li><li><a class="nounderline abstract_t">Chaibi A, Russell MB. Manual therapies for primary chronic headaches: a systematic review of randomized controlled trials. J Headache Pain 2014; 15:67.</a></li><li><a class="nounderline abstract_t">van Ettekoven H, Lucas C. Efficacy of physiotherapy including a craniocervical training programme for tension-type headache; a randomized clinical trial. Cephalalgia 2006; 26:983.</a></li><li><a class="nounderline abstract_t">Mesa-Jiménez JA, Lozano-López C, Angulo-Díaz-Parreño S, et al. Multimodal manual therapy vs. pharmacological care for management of tension type headache: A meta-analysis of randomized trials. Cephalalgia 2015; 35:1323.</a></li><li><a class="nounderline abstract_t">Rolle G, Tremolizzo L, Somalvico F, et al. Pilot trial of osteopathic manipulative therapy for patients with frequent episodic tension-type headache. J Am Osteopath Assoc 2014; 114:678.</a></li><li><a class="nounderline abstract_t">Varangot-Reille C, Suso-Martí L, Romero-Palau M, et al. Effects of Different Therapeutic Exercise Modalities on Migraine or Tension-Type Headache: A Systematic Review and Meta-Analysis with a Replicability Analysis. J Pain 2022; 23:1099.</a></li></ol></div><div id="topicVersionRevision">Topic 3360 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10993991" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20482606" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : EFNS guideline on the treatment of tension-type headache - report of an EFNS task force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12230591" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Migraine: preventive treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21247362" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treating tension-type headache -- an expert opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15509464" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Behavioral interventions for tension-type headache: overview of current therapies and recommendation for a self-management model for chronic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20028727" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Lack of benefit for prophylactic drugs of tension-type headache in adults: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28721535" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tricyclic and Tetracyclic Antidepressants for the Prevention of Frequent Episodic or Chronic Tension-Type Headache in Adults: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15109513" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11075846" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Amitriptyline reduces myofascial tenderness in patients with chronic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11037746" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Central sensitization in tension-type headache--possible pathophysiological mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8795600" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282046" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pharmacoprophylaxis of tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7892022" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chronic tension-type headache: amitriptyline reduces clinical headache-duration and experimental pain sensitivity but does not alter pericranial muscle activity readings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9277026" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Protriptyline, chronic tension-type headaches, and weight loss in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159466" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17346304" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25931277" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694042" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16961787" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A prospective, open-label, long-term study of the efficacy and tolerability of topiramate in the prophylaxis of chronic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1468911" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10971659" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Modified-release formulation of tizanidine in chronic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12167135" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12603653" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tizanidine is not a cure for chronic daily headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16514501" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Combination of tizanidine and amitriptyline in the prophylaxis of chronic tension-type headache: evaluation of efficacy and impact on quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23839118" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy of local lidocaine application on anxiety and depression and its curative effect on patients with chronic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23698019" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lidocaine injection of pericranial myofascial trigger points in the treatment of frequent episodic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36786349" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The effectiveness of botulinum toxin for chronic tension-type headache prophylaxis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15921506" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Behavioral headache treatment: history, review of the empirical literature, and methodological critique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12206049" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Behavioral management of recurrent headache: three decades of experience and empiricism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8316392" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19556046" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Behavioral management of headache triggers: Avoidance of triggers is an inadequate strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19499626" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Behavioral treatments of chronic tension-type headache in adults: are they beneficial?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18540732" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Meta-analysis of biofeedback for tension-type headache: efficacy, specificity, and treatment moderators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11325322" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27092807" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acupuncture for the prevention of tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16430123" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The acupuncture randomised trial (ART) for tension-type headache--details of the treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16055451" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Acupuncture in patients with tension-type headache: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26229071" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy of interventions used by physiotherapists for patients with headache and migraine-systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266458" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Non-invasive physical treatments for chronic/recurrent headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22364330" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Muscle trigger point therapy in tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24623124" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Evidence for the use of dry needling and physiotherapy in the management of cervicogenic or tension-type headache: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25278005" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Manual therapies for primary chronic headaches: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886935" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy of physiotherapy including a craniocervical training programme for tension-type headache; a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25748428" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Multimodal manual therapy vs. pharmacological care for management of tension type headache: A meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25170037" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pilot trial of osteopathic manipulative therapy for patients with frequent episodic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34929374" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of Different Therapeutic Exercise Modalities on Migraine or Tension-Type Headache: A Systematic Review and Meta-Analysis with a Replicability Analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
